Alliance for Pandemic Preparedness

May 4, 2020

Remdesivir in Adults with Severe COVID-19 : A Randomised, double-blind, placebo-controlled, multicentre trial

Category:

Topic:

  • A randomized, double-blind, placebo controlled multicenter trial at ten hospitals in Hubei, China with 237 participants (158 randomized to remdesivir, 79 to placebo) demonstrated that time to clinical improvement did not differ by study arm, with 21 days (IQR 13-28 days) in the remdesivir group versus 23 days (IQR 15-28 days) in the placebo group (HR 1.23, 95% CI 0.87 – 1.75). Overall frequency of adverse events was similar in both groups; however treatment cessation due to adverse events was higher in the remdesivir (12%) than placebo (5%) group.  

Wang et al. (Apr 29, 2020). Remdesivir in Adults with Severe COVID-19 : A Randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. https://doi.org/10.1016/S0140-6736(20)31022-9